Literature DB >> 23110487

Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article.

Peter Rolny1, Morten Vatn.   

Abstract

Corticosteroids are the mainstay of therapy for severe ulcerative colitis. However, at least a third of patients fail to respond and face a colectomy. In these, rescue therapy with cyclosporine or infliximab (IFX), aimed at avoiding surgery, has been used in recent years. Of the two options, infliximab is largely preferred in both Sweden and Norway, whereas cyclosporine (CyA) is generally regarded as difficult to use, rather toxic and showing limited long-term efficacy. In light of some new recent data, herein, we provide an update of the literature in the field. It appears that there are theoretical and practical arguments on each side, and as of today, the choice between IFX or CyA for rescue therapy cannot be made on strong evidence. Thus, the best choice of medical rescue therapy will depend on the results of ongoing RCTs as well as future research in the field.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23110487     DOI: 10.3109/00365521.2012.733954

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  5 in total

1.  Long-term outcome of cyclosporin rescue therapy in acute, steroid-refractory severe ulcerative colitis.

Authors:  Tamás Molnár; Klaudia Farkas; Zoltán Szepes; Ferenc Nagy; Mónika Szűcs; Tibor Nyári; Anita Bálint; Tibor Wittmann
Journal:  United European Gastroenterol J       Date:  2014-04       Impact factor: 4.623

2.  Usefulness of the cytomegalovirus antigenemia assay in patients with ulcerative colitis.

Authors:  Jaeyoung Chun; Changhyun Lee; Ji-Eun Kwon; Sung Wook Hwang; Sang Gyun Kim; Joo Sung Kim; Hyun Chae Jung; Jong Pil Im
Journal:  Intest Res       Date:  2015-01-29

3.  Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study.

Authors:  Eun Hye Kim; Duk Hwan Kim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Gut Liver       Date:  2015-09-23       Impact factor: 4.519

Review 4.  Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis.

Authors:  Yi-Juan Liu; Hua Fan; Wei-Wei Zhen; Xing Yu; Jin-Tong Chen; Cheng-Dang Wang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

5.  Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis.

Authors:  Kata Szemes; Alexandra Soós; Péter Hegyi; Nelli Farkas; Adrienn Erős; Bálint Erőss; Emese Mezősi; Zsolt Szakács; Katalin Márta; Patrícia Sarlós
Journal:  Front Med (Lausanne)       Date:  2020-01-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.